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Abstract
Background: Triple-negative breast cancer (estrogen receptor-, progesterone receptor-, and
HER2-negative) (TNBC) is a high risk breast cancer that lacks specific therapy targeting these
proteins.
Methods: We studied 969 consecutive Japanese patients diagnosed with invasive breast cancer
from January 1981 to December 2003, and selected TNBCs based on the immunohistochemical
data. Analyses of epidermal growth factor receptor (EGFR) gene mutations and amplification, and
BRCA1 mRNA expression were performed on these samples using TaqMan PCR assays. The
prognostic significance of TNBCs was also explored. Median follow-up was 8.3 years.
Results: A total of 110 (11.3%) patients had TNBCs in our series. Genotyping of the EGFR gene
was performed to detect 14 known EGFR mutations, but none was identified. However, EGFR gene
copy number was increased in 21% of TNBCs, while only 2% of ER- and PgR-positive, HER2-
negative tumors showed slightly increased EGFR gene copy numbers. Thirty-one percent of TNBCs
stained positive for EGFR protein by immunohistochemistry. BRCA1 mRNA expression was also
decreased in TNBCs compared with controls. Triple negativity was significantly associated with
grade 3 tumors, TP53 protein accumulation, and high Ki67 expression. TNBC patients had shorter
disease-free survival than non-TNBC in node-negative breast cancers.
Conclusion: TNBCs have an aggressive clinical course, and EGFR and BRCA1 might be candidate
therapeutic targets in this disease.
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Background
Although the overall mortality due to breast cancer in the
United States has decreased, attributed in part to breast
screening and early application of various treatments,
overall mortality in Japan is still increasing [1]. Breast can-
cers represent a heterogeneous group of tumors that are
diverse in behavior, outcome, and sensitivity to therapy.
To reduce mortality from breast cancer, it would be desir-
able to identify and characterize tumors having a poor
prognosis. Emerging data demonstrate that stratification
of tumors by gene expression profiles divides breast can-
cer into four common subtypes which are associated with
different clinical outcome [2]. Two of them are estrogen
receptor (ER)-positive (luminal and luminal/HER2+) and
two are ER-negative (basal-like and HER2 positive) [2,3].
Although the immunohistochemical staining profile can
be a useful surrogate for gene expression analysis, the
optimum immunohistochemical profile of the basal-like
subtype remains unclear. However, the basal-like category
is composed almost entirely of triple-negative breast can-
cers (TNBCs) (i.e., tumors lacking ER, progesterone recep-
tor (PgR) and HER2 expression) [3-5]. A simplified
method of classification, based on immunohistochemical
assays for ER, PgR, and HER2, is clinically useful, and cli-
nicians are increasingly taking triple-negative status into
account in clinical decision-making and therapeutic pro-
tocol design. Epidermal growth factor receptor (EGFR) is
more frequently expressed in TNBCs than in non-TNBCs
[6,7]. Therefore, the EGFR is considered a candidate treat-
ment target for TNBCs.
Cluster analyses of microarray expression profiling data
have shown that familial BRCA1 mutant tumors tend to
fall into the basal-like category [2]. Some studies have
indicated that BRCA1 mRNA expression is lower in basal-
like sporadic cancers [8], and in approximately 30% of
sporadic breast cancers [9]. It is believed that this may be
the result of an epigenetic mechanism acting on the
BRCA1 gene or a dysfunction in the upstream pathways
regulating  BRCA1  expression [8,10]. These sporadic
tumors with reduced BRCA1 expression tend to be triple-
negative, and remarkably similar to BRCA1-mutated
tumors [8].
Here, we present data on a large series of TNBCs with
long-term follow-up and data on the status of their EGFR
and BRCA1 genes.
Methods
Patients
A total of 969 surgically resected breast carcinomas with
tissue blocks available were selected from the archive of
the Department of Breast and Endocrine Surgery, Nagoya
City University Hospital in Japan. Specimens were
obtained from patients who underwent surgery between
January 1981 and December 2003. Tissues were fixed in
10% buffered formalin and embedded in paraffin or
placed in liquid nitrogen immediately after resection and
stored at -80°C until DNA and RNA extraction. Informed
consent was obtained before the surgery. The histological
grade was estimated according to the Bloom and Richard-
son method proposed by Elston and Ellis [11]. Analysis of
clinical outcome was performed in a total of 557 consec-
utive breast cancer patients operated from January 1981 to
December 1999, because their clinicopathological and
survival data were available for this study. Disease-free
survival (DFS) was defined as the interval from the date of
primary surgery to the first locoregional recurrence or dis-
tant metastasis. The distant disease-free survival (DDFS)
was defined as the interval from the date of primary sur-
gery to the identification of distant metastasis. The
median follow-up period was 8.3 years (range 3 to 281
months). Relapse data were available in 543 of 557
patients examined: 159 (28.5%) experienced disease
recurrence; 99 (17.7%) showed distant relapse; and 75
(13.4%) had died. This protocol was approved by the
Institutional Review Board of Nagoya City University
Graduate School of Medical Sciences.
DNA and RNA extraction
Genomic DNA and total RNA from homogeneous micro-
scopically confirmed breast cancer tissues was isolated
from approximately 500 mg of each frozen specimen
using a phenol-chloroform extraction method for DNA
extraction, and with TRIZOL reagent (Invitrogen Japan
K.K., Tokyo, Japan) for RNA extraction according to the
manufacturer's recommendations. Total RNA was also
isolated from MCF-7 cells with TRIZOL reagent (Invitro-
gen).
Immunohistochemical analysis
One 4-μm section from each paraffin block specimen was
first stained with hematoxylin and eosin in order to ascer-
tain that an adequate number of invasive ductal carci-
noma cells were present and that quality of fixation was
adequate for immunohistochemical analysis. Serial sec-
tions (4-μm) were then prepared from suitable blocks and
float-mounted on adhesive-coated glass slides for ERα,
PgR, HER2, TP53, Ki67, cytokeratin (CK) 5/6, CK14 and
EGFR staining. Primary antibodies were mouse mono-
clonal anti-human antibodies against ERα (1D5; DAKO,
Glostrup, Denmark) at a 1:100 dilution, PgR (PgR636;
DAKO) at a 1:100 dilution, TP53 (PAb1801; Novocastra,
Newcastle, UK) at 1:50, Ki67 (MIB-1; DAKO) at 1:100,
CK5/6 (D5/16 B4; DAKO) at 1:50 and CK14 (LL002; Neo-
Markers, Fremont, CA) at 1:200. Rabbit anti-human c-
erbB2 oncoprotein antibody (DAKO) at a 1:200 dilution
was used for HER2. The DAKO EnVision system (DAKO
EnVision-labeled polymer, peroxidase) was used forBMC Cancer 2008, 8:309 http://www.biomedcentral.com/1471-2407/8/309
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detection of ERα, PgR, HER2, Ki67, CK5/6, and CK14. The
streptavidin-biotin system (SAB-PO kit; Nichirei Co., Inc.,
Tokyo, Japan) was applied for detection of the bound
TP53 antibody. Immunostaining for EGFR was performed
using the EGFRpharmDx assay detection system (predi-
luted; DAKO).
Interpretation of immunohistochemical staining
Immunostained specimens were scored after the entire
slide had been evaluated by light microscopy. The expres-
sion of ERα was scored by assigning a proportion score
and an intensity score according to Allred's procedure
[12]. Any brown nuclear staining in invasive breast epi-
thelium was counted toward the proportion score.
Tumors with scores of 3 or greater were considered to be
positive for ERα expression. HER2 immunostaining was
evaluated using the same method as is employed by the
HercepTest (DAKO). To determine the score of HER2
expression the membrane staining pattern was estimated
and scored on a scale of 0 to 3+. Tumors with scores of 0
and 1 were considered to be negative, and tumors with a
score of 3 were considered to be positive for HER2 overex-
pression. All tumors with a score of 2 were omitted from
the analysis in this study because fluorescent in situ
hybridization (FISH) analysis was not carried out on
them. In the case of TP53, tumors were considered immu-
nohistochemically positive when ≥ 10% of the tumor cells
showed nuclear staining [13,14]. The expression status of
Ki67 was assessed according to the estimated proportion
of nuclear staining of tumor cells that were positively
stained. Scoring criteria for Ki67 were as follows (in the
form proportion of nuclear staining = score): none = 0,
<1/100 = 1, 1/100-1/10 = 2, 1/10-1/2 = 3, and >1/2 = 4
[15]. Tumors with a score of 3 or greater for Ki67 were
considered to have high Ki67 expression. Positivity for
CK5/6 and CK14 was defined as the detection of more
than 5% of invasive tumor cells showing strong cytoplas-
mic and membrane staining [16]. Immunostaining for
EGFR was interpreted as positive when at least 10% of
tumor cells showed strong membrane staining [7,17].
Genetic analysis of EGFR
The primers and TaqMan probes were designed for 14
known mutations in the EGFR gene [18]. TaqMan geno-
typing assays for EGFR  mutations were performed on
Applied Biosystems 7500 Fast Real-Time PCR equipment
(Applied Biosystems) as described previously [18]. The
results were analyzed using the allelic discrimination
assay program [18].
Real-Time Reverse Transcription (RT)-PCR
RT was performed as described previously [22]. Real-time
quantitative RT-PCR of the BRCA1 gene was performed
using TaqMan Universal PCR Master Mix (Applied Biosys-
tems) in the Applied Biosystems 7500 Fast Real-Time PCR
System, following the manufacturer's instructions. The
primers and probes for the BRCA1  mRNA expression
assay are commercially available (TaqMan Gene Expres-
sion Assays, Assay ID: Hs00173233_m1, Applied Biosys-
tems). The PCR conditions were as follows: initial
denaturation at 95°C for 2 sec, followed by 40 cycles of
95°C for 3 sec, and 60°C for 30 sec. To ensure the fidelity
of mRNA extraction and reverse transcription, BRCA1 sig-
nals from all samples were normalized against GAPDH as
an internal control. The primers and probes for GAPDH
mRNA expression assay are commercially available (Taq-
Man Gene Expression Assays, Assay ID: Hs99999905_m1,
Applied Biosystems). The PCR conditions for amplifica-
tion of GAPDH were as follows: initial denaturation at
95°C for 2 sec, followed by 40 cycles of 95°C for 3 sec,
and 60°C for 30 sec. For each PCR run, a standard curve
was constructed with serial dilutions of cDNA obtained
from MCF-7 cells, which express BRCA1 mRNA.
Statistical analyses
All molecular and immunohistochemical analyses were
performed blinded to clinical data. Statistical calculations
were performed with StatView-J 5.0 software (SAS Insti-
tute Inc., Cary, NC). The relationship between the fre-
quency of TNBC or non-TNBC and clinicopathologic
factors were assessed by χ2 and Fisher's exact probability
tests. The Mann-Whitney U-test was performed for the
analyses of the EGFR  gene copy number and BRCA1
mRNA expression. DFS and DDFS curves were generated
by the Kaplan-Meier method and verified by the log-rank
test. Cox proportional hazards regression analysis was
used for univariate and multivariate analyses of prognos-
tic values. Differences were considered significant when a
P value < 0.05 was obtained.
Results
Patient Characteristics and Immunohistochemical results
In total, 969 Japanese cases of invasive breast cancer
undergoing surgery at Nagoya City University Hospital
from January 1981 to December 2003 were informative
for the 3 markers ER, PgR, and HER2. Of these informative
cases, 110 (11.3%) were found to be TNBCs. Immunohis-
tological analyses of TP53 and Ki67, and clinicopatholog-
ical analysis were performed in 531 consecutive patients
from 1981 to 1999. Table 1 shows the features of 71
TNBCs compared with 415 non-TNBCs concerning differ-
ent clinicopathological variables and biomarkers. All
tumors with a HER2 score 2+ were omitted from this anal-
ysis, as indicated in Methods. TNBC was significantly
associated with grade 3 tumors (P < 0.0001), with TP53
protein accumulation (P < 0.0001) and with high Ki67
expression (P < 0.0001), as well as lymph node status (P
= 0.02).BMC Cancer 2008, 8:309 http://www.biomedcentral.com/1471-2407/8/309
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Next, immunohistological analyses of EGFR, CK 5/6, and
CK14 were performed for all TNBCs available in this
study, operated from January 1981 to December 2003. As
shown in Table 2, 31% (33 cases) of TNBC were positive
for EGFR protein, 52% (57 cases) expressed CK5/6, and
55% (61 cases) CK14. A total of 77 (70%) had a basal-like
phenotype according to Nielsen's definition (TNBC with
CK5/6 and/or EGFR expression) [3,4].
Genomic analysis of EGFR
We sought mutations in the EGFR gene in TNBCs, because
EGFR mutations were found in a subset of Japanese non-
small lung cancers, despite being very rare in Caucasians
[23], and because these mutations were suggested to pre-
dict responses to gefitinib therapy [23,24]. The sequences
of primers and probes in TaqMan genotyping assays for
the EGFR gene are shown in Table 3. Genomic DNA was
available in 63 of 110 TNBC tissues, and genotyping
could be successfully performed for the 14 known EGFR
mutations in 58 of these. However, none of the 58 TNBC
showed any known EGFR  mutations. We previously
reported an increased EGFR copy number in a subset of
Japanese non-small lung cancers [18]. As 31% of TNBCs
were positive for EGFR protein in this series, we measured
EGFR gene copy number in 63 TNBCs compared with 42
ER and/or PgR-positive but HER2-negative consecutive
breast cancers, (which are also termed luminal subtype
[2]). It was found that 21% (12 cases) of TNBCs contained
an increased EGFR  gene copy number while only one
(2%) of luminal subtype tumors showed slightly
increased  EGFR  gene copy (Mann-Whitney U-test: P  =
0.016, Fig. 1). We then sought any correlations between
the EGFR gene copy number and EGFR protein expression
based on the immunohistochemical analysis in TNBCs.
Only 2 of 14 TNBCs showing EGFR protein expression
demonstrated increased EGFR gene copy number (Table
4). There were no significant correlations between these
parameters.
EGFR gene copy numbers in breast cancer tissues were
estimated with 7500 Fast Real-Time PCR using a Quanti-
Tect SYBR Green Kit (Qiagen Inc, Valencia, CA) as
described previously [18]. Briefly, we have quantified each
tumor DNA by comparing the target locus to the reference
Line-1, a repetitive element for which copy numbers per
haploid genome are similar among all normal and neo-
Table 1: Characteristics of Patients with Different Tumor Subtypes
Variables Total Triple negative Non-triple negative P value
N = 486 (100%) N = 71 (15%) N = 415 (85%)
No. % No. % No. %
Age, years 0.49
≤50 198 41 32 44 166 40
>50 288 59 39 56 249 60
Size 0.23
≤2 cm 181 37 21 30 160 39
>2 cm 288 59 46 65 242 58
Unknown 17 4 5 13 3
Nodal status 0.02
Negative 275 57 48 68 227 55
Positive 192 40 19 27 173 42
Unknown 19 3 4 5 15 3
Histology 0.14
Ductal 454 94 66 93 388 93
Lobular 16 3 0 0 16 4
Other 16 3 5 7 11 3
Grade <0.0001
19 2 1 9 4 6 8 8 2 1
2 273 56 32 45 241 58
3 101 21 34 48 67 16
Unknown 20 4 1 1 19 5
TP53 expression <0.0001
Negative 392 81 43 61 349 84
Positive 92 19 28 39 64 15
Unknown 2 0 0 0 2 1
Ki67 expression <0.0001
Low 333 69 34 48 299 72
High 150 31 37 52 113 27
Unknown 3 1 0 0 3 1BMC Cancer 2008, 8:309 http://www.biomedcentral.com/1471-2407/8/309
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plastic human cells [19,20]. The relative EGFR  copy
number level was normalized to normal human genomic
DNA as the calibrator. Copy number changes relative to
the Line-1 gene and the calibrator were determined by the
formula (TEGFR/TLine-1)/(CEGFR/CLine-1), where TEGFR/TLine-1
are quantity from tumor DNA by using EGFR and Line-1,
and CEGFR/CLine-1 are quantity from calibrator by using
EGFR and Line-1 [19,20]. Primer sequences for the EGFR
gene used in this study were: forward, CCACCAAATT-
AGCCTGGACA; reverse, CGCGACCCTTAGGTATTCTG.
EGFR gene copy number > 3 was defined as positive [21].
BRCA1 mRNA expression analysis
Loss of BRCA1 function has been found in basal-like
breast cancer. Therefore, we assessed BRCA1  mRNA
expression in 61 TNBC and 60 consecutive luminal sub-
type breast cancers. As shown in Fig. 2, BRCA1 mRNA
expression was significantly decreased in TNBCs com-
pared to luminal subtype breast cancers. BRCA1  gene
mutations were not analyzed in this study. Therefore,
TNBCs in our series may include both BRCA1-mutant and
sporadic TNBCs. Nonetheless, the fact remains that signif-
icantly reduced BRCA1 mRNA expression was observed in
these Japanese TNBCs.
Clinical outcome by treatment epoch
Although adjuvant therapies are effective in breast can-
cers, their employment was not yet standard practice in
Japan in the 1980's. Here, we first compared the outcome
for breast cancer patients treated at Nagoya City Univer-
sity Hospital in the 1980's with those treated in the
1990's. All patients treated later tended to show better
DDFS compared with those treated in the 1980's (Fig. 3a).
Patients with tumors of luminal subtype treated in the
1990's showed significantly better DDFS than those from
the 1980's (P = 0.02, Fig. 3b). In contrast, DDFS of
patients with TNBC treated either in the 1980's or 1990's
was similar (Fig. 3c). Only 58% (61/106 cases) of patients
with luminal subtype tumors treated in the 1980's
received adjuvant tamoxifen therapy while this figure
increased to 78% (194/248 cases) in the 1990's. There-
fore, a higher rate of adjuvant hormone therapy might be
associated with better DDFS in patients with luminal sub-
type tumors. For TNBCs, 31% (12/39 cases) treated in the
1980's received chemotherapy (10 patients received oral
5-fluorouracil (5-FU), and 2 were treated with an anthra-
cycline-based regimen) while 38% (12/32 cases) received
chemotherapy in the 1990's (11 oral 5-FU, and one CMF
(cyclophosphamide/methotrexate/5-FU)-based regi-
men). Because both the percentage of patients on adju-
vant therapy and the adjuvant chemotherapy regimens
themselves were similar for TNBC patients in the 1980's
and the 1990's, the outcomes in these two treatment
epochs were considered to be similar.
Clinical outcome according to tumor subtype
Next, we analyzed the outcome of all patients treated from
1981 to 1999 (n = 531) to compare TNBCs with non-
TNBCs. We found that TNBC was not associated with
poor DDFS overall (Fig. 4a). Non-TNBC were classified
into 3 subtypes as follows: 1) luminal subtype (ER+ and/
or PgR+ and HER2-), 2) luminal/HER2+ subtype (ER+
and/or PgR+ and HER2+), and 3) HER2+ subtype (ER-
and PgR- and HER2+) [3]. Within 5 years of diagnosis, the
Kaplan-Meier survival curves of TNBC and HER2+ sub-
type patients were similar (Fig. 4b). Thereafter, however,
the survival curve of TNBCs more closely approximated
luminal subtype. DDFS was significantly different
between luminal and luminal/HER2+ subtypes (P =
0.0008) but not between TNBC and any other subtype
(Fig. 4b). For luminal/HER2+ subtype patients, 6 (27%)
received no adjuvant therapy and 7 (32%) received adju-
vant tamoxifen alone. Therefore, patients with luminal/
HER2+ subtype tumor could be considered to have been
under-treated in this series.
In our series, 68% of TNBCs were node-negative but only
53% of non-TNBCs (P = 0.02, Table 1). Therefore, we next
analyzed the clinical outcome only in node-negative
breast cancers. Fifteen patients (31%) having node-nega-
tive TNBC received adjuvant chemotherapy (13 oral 5-FU,
and 2 anthracycline-based regimen) while 26 (54%)
received no adjuvant therapy. Medical records of 7
patients (15%) having node-negative TNBC were missing.
The results show that node-negative TNBC was associated
Table 2: Immunohistochemical Findings in Triple Negative 
Breast Cancer
Variables Triple negative (N = 110)
No. %
EGFR
Negative 69 62
Positive 33 31
Unknown 8 7
Cytokeratin 5/6
Negative 47 43
Positive 57 52
Unknown 6 5
Cytokeratin 14
Negative 43 40
Positive 61 55
Unknown 6 5
Cytokeratin 5/6/14
Negative 32 30
Posotive 72 65
Unknown 6 5
Basal-like phenotype
Negative 24 22
Positive 77 70
Unknown 9 8BMC Cancer 2008, 8:309 http://www.biomedcentral.com/1471-2407/8/309
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Table 3: Sequence of the mutation-specific TaqMan probes and PCR primers for the EGFR gene
Mutation No. Probe name Nucleotide Amino Acid Primer sequence 
(forward)
WT1 CCCAGAAGGTGAGAAAG
TTAAAATTC
1 Del 1a 2235-2249del E746-A750del (same as above)
2 Del 1b 2236-2250del (same as above)
3 Del 2 2254-2277del S752-I759del (same as above)
WT2 (same as above)
4 Del 3 2239-2247del, 2248G>C L747-E749del, A750P (same as above)
5 Del 4 2240-2257del L747-S752del, P753S (same as above)
6 Del 5 2238-2255del, 2237A>T L747-A750del, E746V (same as above)
7 Del 6 2240-2251del L747-A750del, T747S (same as above)
WT3 TGAGGATCTTGAAGGAAA
CTGAATTC
8 G719C 2155G>T G719C (same as above)
9 G719S 2155G>A G719S (same as above)
WT4 CCGCAGCATGTCAAGAT
CAC
10 L858R 2573T>G L858R (same as above)
WT5 (same as above)
11 L861Q 2582T>A L861Q (same as above)
WT6 CCCAGAAGGTGAGAAAG
TTAAAATTC
12 L747Del 2239-2262del L747-K754del (same as above)
13 N756Ins 2265-2267InsCAA N756Ins (same as above)
WT7 GGAGGACCGTCGCTTGG
T
14 L838P 2513T>C L838P (same as above)
TaqMan probe Primer sequence 
(reverse)
VIC-
ATTAAGAGAAGCAACATC
T
CCCACACAGCAAAGCAG
AAA
FAM-
CGCTATCAAAACATCT
(same as above)
FAM-
CTATCAAGACATCTCC
(same as above)
FAM-
AGAAGCAACACTCGAT
(same as above)
VIC-CGAAAGCCAACAAG (same as above)
FAM-
CAAGGAACCAACATC
(same as above)
FAM-
AAGGAATCGAAAGCC
(same as above)
FAM-
CAAGGTTCCGAAAGC
(same as above)
FAM-
TCAAGGAATCATCTCC
(same as above)
VIC-AAGTGCTGGGCTCC TGCCAGGGACCTTACCT
TATACA
FAM-
AAAGTGCTGTGCTCC
(same as above)
FAM-
AAAGTGCTGTGCTCC
(same as above)
VIC-TTGGGCTGGCCAAA TCCTTCTGCATGGTATTC
TTTCTCT
FAM-TTGGGCGGGCCAA (same as above)
VIC-CCAAACTGCTGGGTG (same as above)
FAM-
CCAAACAGCTGGGTG
(same as above)BMC Cancer 2008, 8:309 http://www.biomedcentral.com/1471-2407/8/309
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with shorter DDFS than node-negative non-TNBC (Fig.
4c). When DDFS of node-negative TNBCs was compared
with other subtypes, a significant difference was observed
only between TNBC and luminal subtype (Fig. 4d). As
shown in Fig. 4e, grade 1 node-negative TNBCs demon-
strated no distant metastasis. However, the number of
these patients was very small. Univariate Cox regression
analysis indicated that only nodal status was associated
with DDFS in TNBCs (Table 5).
Discussion
Although adjuvant hormone therapy was shown to be
effective for ER-positive breast cancers [25], and adjuvant
trastuzumab therapy was also shown to improve the sur-
vival of HER2 positive breast cancers [26,27], TNBCs have
no targeted therapy at present. We screened TNBCs for 14
known EGFR mutations previously reported in lung can-
cers [18] but failed to find any. Gefitinib was reported to
be effective not only in lung cancers with EGFR mutations
[23,24,28], but also for lung or colorectal cancers express-
ing EGFR protein or with increased EGFR  gene copy
number [20,29]. In our study, 31% of TNBCs were found
to express EGFR protein, so could be candidates for gefit-
inib therapy. We also analyzed EGFR gene copy numbers
of TNBCs by the PCR method [19-21], and found fre-
quent increases in TNBCs compared with luminal subtype
breast cancers. Although lung cancers having EGFR muta-
tions were reported to be responsive to gefitinib therapy,
about 10% of lung cancers without EGFR mutations were
also susceptible to this therapy [28]. Therefore, even
though no EGFR mutations were found in TNBCs in this
study, TNBCs with increased EGFR  gene copy number
might still be candidates for therapy with anti-EGFR mon-
oclonal antibodies such as gefitinib. We performed FISH
assays on representative tumors with increased EGFR copy
number [30] but could not compare the PCR and FISH
assays. The reason for this was most likely the condition
of the paraffin-embedded tissues not being good enough,
because we did not see either EGFR or CEP7 signals as a
control (data not shown). In our study, EGFR protein
expression was not consistently accompanied by
increased EGFR gene copy number. One of the reasons for
lack of correlation between EGFR gene copy number and
immunohistochemistry could be the technique used in
this study. EGFR protein expression is generally heteroge-
neous. If a frozen tissue with PCR technique is used, it is
subjected to the "dilution effect" and could be responsible
for non-correlation in at least some cases. In lung cancers,
increased EGFR gene copy number was also reported not
to be consistently accompanied by positivity for EGFR
protein, as assessed by immunohistochemistry [32].
Although we did not obtain FISH data for TNBCs with
increased EGFR gene copy numbers, we are confident that
the EGFR gene copy number data are reliable because the
methodology to measure this gene is well-established [19-
21], and in this series a significant difference in EGFR gene
copy number was observed between TNBCs and luminal
subtype tumors.
Basal-like breast cancer was reported to frequently possess
BRCA1  germline mutations [2], and BRCA1  mRNA
expression was also shown to be lower in sporadic basal-
VIC-
ATTAAGAGAAGCAACATC
T
CCCACACAGCAAAGCAG
AAA
FAM-
CTATCAAGGAAGCCAACA
A-MGB
(same as above)
FAM-
CCAACAACAAGGAAAT-
MGB
(same as above)
VIC-CGCGACCTGGCAG-
MGB
CCCAAAATCTGTGATCTT
GACATG
FAM-CGCGACCCGGCAG-
MGB
(same as above)
Table 3: Sequence of the mutation-specific TaqMan probes and PCR primers for the EGFR gene (Continued)
Table 4: Relationship between EGFR Copy Number and the Immunohistochemical staining of EGFR protein in Triple Negative Breast 
Cancer
Increased EGFR gene copy No. No increased EGFR gene copy No.
EGFR IHC
04 1 4
16 2 2
22 8
30 2
IHC, immnohistochemistryBMC Cancer 2008, 8:309 http://www.biomedcentral.com/1471-2407/8/309
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like breast cancers [8]. The profound similarities between
hereditary  BRCA1-related breast cancers and basal-like
breast cancers suggest a fundamental defect in the BRCA1
pathway in sporadic basal-like breast cancers [33,34].
Recently, BRCA1 has been demonstrated to play a critical
role in the differentiation of ER-negative stem/progenitor
cells to ER-positive luminal cells, and it was reported that
loss of BRCA1 function resulted in the accumulation of
ER-negative stem/progenitor cells, candidates for a cancer
stem cell in the basal-like subtype [35]. BRCA1 was dem-
onstrated to have an important role for DNA double-
strand break repair by homologous recombination [36].
Epidermal growth factor receptor (EGFR) gene copy number  in triple-negative and luminal subtypes in Japanese breast can- cer patients Figure 1
Epidermal growth factor receptor (EGFR) gene copy 
number in triple-negative and luminal subtypes in 
Japanese breast cancer patients.
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Distant disease-free survival (DDFS) according to breast cancer subtype Figure 4
Distant disease-free survival (DDFS) according to breast cancer subtype. (a)(b) all patients, (c)(d) node-negative 
patients alone, (e) node-negative triple-negative breast cancer patients alone.
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Poly(ADP-ribose) polymerase (PARP) is an enzyme
involved in base excision repair, a key pathway in the
repair of DNA single-strand breaks [37]. Recently, BRCA1/
2 dysfunction has been shown to sensitize cells to the
inhibition of PARP enzymatic activity [38]. Therefore,
PARP inhibitors may be key drugs for treating TNBCs [38].
Although patients with TNBCs were reported to have a
poor prognosis [6,39], the recurrent pattern of TNBCs was
different from non-TNBCs [40-42]. Dent et al [40]
reported that TNBC patients had an increased likelihood
of recurrence and death within 5 years of diagnosis but
not thereafter, while the recurrent risk among non-TNBCs
was shown to be stable over the period of follow-up.
Liedtke et al [41] described the clinical course of 1,118
breast cancer patients who received neoadjuvant chemo-
therapy. Twenty-three percent of these women had TNBC,
and showed an increased likelihood of 3-year progres-
sion-free survival and 3-year overall survival [41]. The
clinical course of TNBCs in our series was very similar to
these previous reports [40-42].
Patients with TNBC were reported to have increased path-
ological complete response rates (pCR) to neoadjuvant
chemotherapy compared with non-TNBC [41,43,44].
However, TNBC patients with residual disease after neo-
adjuvant chemotherapy had worse survival compared
with non-TNBC patients [41,43]. Carey et al [43] termed
this characteristic of TNBCs "the triple negative paradox".
The higher sensitivity to neoadjuvant chemotherapy in
TNBCs may suggest that patients with TNBC should be
treated more intensively including with novel therapeutic
alternatives. In this series, node-negative TNBCs showed
poorer prognosis than node-negative non-TNBCs. Node-
negative TNBCs could thus be considered to have been
under-treated with adjuvant therapy in this series. On the
other hand, no recurrence occurred in grade 1 node-nega-
tive TNBCs, although this subgroup was very small. This
might indicate another issue as to how to classify TNBCs
into subgroups that would benefit from more intensive
adjuvant therapy. In this study, we did not find any useful
prognostic markers of TNBCs although they showed
higher positivity for TP53 protein accumulation and
higher Ki67 expression.
Conclusion
Frequently increased EGFR copy number and EGFR pro-
tein expression, and decreased BRCA1 mRNA expression,
Table 5: Univariate Cox Regression Analysis of Factors Associated with Distant Disease-free Survival in the Triple-Negative Tumors
Variables P value Relative Risk of recurrence (95% CI)
Size
≤2 cm 1.0 (reference)
>2 cm 0.92 1.26 (0.44 to 3.65)
Nodal status
Negative 1.0 (reference)
Positive 0.02 2.60 (1.14 to 6.96)
Grade
1 1.0 (reference)
2, 3 0.22 2.46 (0.68 to 10.39)
TP53 expression
Negative 1.0 (reference)
Positive 0.61 1.12 (0.72 to 1.77)
Ki67 expression
Low 1.0 (reference)
High 0.55 0.88 (1.59 to 1.34)
EGFR IHC
Negative 1.0 (reference)
Positive 0.88 1.07 (0.48 to 2.36)
EGFR gene copy number
<3 1.0 (reference)
≥3 0.2 0.27 (0.03 to 2.05)
Cytokeratins
Negative 1.0 (reference)
Positive 0.42 0.72 (0.33 to 1.68)
Basal like type
+ 1.0 (reference)
- 0.67 0.79 (0.34 to 1.80)
IHC, immunohistochemistryBMC Cancer 2008, 8:309 http://www.biomedcentral.com/1471-2407/8/309
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were observed in Japanese triple-negative breast cancers.
EGFR and BRCA1 might be candidates for targeted thera-
pies.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
TT conceived and designed the study and drafted the man-
uscript. NK carried out mRNA expression assay. TT, HY
and ST carried out immunohistochemical analysis. KO
and HS carried out mutation and amplification assays. HI
and YF were involved in data acquisition and interpreta-
tion. All authors read and approved the final manuscript.
Acknowledgements
This work was supported by a Grant-in-Aid for Scientific Research from the 
Ministry of Education, Culture, Sports, Science, and Technology of Japan, 
grant # 19390367.
References
1. Parkin DM, Whelan SL, Ferlay J, Teppo L, Thomas DB: Cancer Inci-
dence in Five Continents Lyon: IARC; 2002. 
2. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S,
Johnsen H, Pesich R, Geisler S, et al.: Repeated observation of
breast tumor subtypes in independent gene expression data
sets.  Proc Natl Acad Sci USA 2003, 100:8418-8423.
3. Cheang MC, Voduc D, Bajdik C, Leung S, McKinney S, Chia SK, Perou
CM, Nielsen TO: Basal-like breast cancer defined by five
biomarkers has superior prognostic value than triple-nega-
tive phenotype.  Clin Cancer Res 2008, 14:1368-1376.
4. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernan-
dez-Boussard T, Livasy C, Cowan D, Dressler L, et al.: Immunohis-
tochemical and clinical characterization of the basal-like
subtype of invasive breast carcinoma.  Clin Cancer Res 2004,
10:5367-5374.
5. Diaz LK, Cryns VL, Symmans WF, Sneige N: Triple negative breast
carcinoma and the basal phenotype: from expression profil-
ing to clinical practice.  Adv Anat Pathol 2007, 14:419-430.
6. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO:
Prognostic markers in triple-negative breast cancer.  Cancer
2007, 109:25-32.
7. Kim MJ, Ro JY, Ahn SH, Kim HH, Kim SB, Gong G: Clinicopatho-
logic significance of the basal-like subtype of breast cancer: a
comparison with hormone receptor and Her2/neu-overex-
pressing phenotypes.  Hum Pathol 2006, 37:1217-1226.
8. Turner NC, Reis-Filho JS, Russell AM, Springall RJ, Ryder K, Steele D,
Savage K, Gillett CE, Schmitt FC, Ashworth A, Tutt AN: BRCA1
dysfunction in sporadic basal-like breast cancer.  Oncogene
2007, 26:2126-2132.
9. Yang Q, Sakurai T, Mori I, Yoshimura G, Nakamura M, Nakamura Y,
Suzuma T, Tamaki T, Umemura T, Kakudo K: Prognostic signifi-
cance of BRCA1 expression in Japanese sporadic breast car-
cinomas.  Cancer 2001, 92:54-60.
10. Matros E, Wang ZC, Lodeiro G, Miron A, Iglehart JD, Richardson AL:
BRCA1 promoter methylation in sporadic breast tumors:
relationship to gene expression profiles.  Breast Cancer Res Treat
2005, 91:179-186.
11. Elston CW, Ellis IO: Pathological prognostic factors in breast
cancer. I. The value of histological grade in breast cancer:
experience from a large study with long-term follow-up.  His-
topathology 1991, 19:403-410.
12. Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor
status by immunohistochemistry is superior to the ligand-
binding assay for predicting response to adjuvant endocrine
therapy in breast cancer.  J Clin Oncol 1999, 17:1474-1481.
13. Kandioler-Eckersberger D, Ludwig C, Rudas M, Kappel S, Janschek E,
Wenzel C, Schlagbauer-Wadl H, Mittlbock M, Gnant M, Steger G,
Jakesz R: TP53 mutation and p53 overexpression for predic-
tion of response to neoadjuvant treatment in breast cancer
patients.  Clin Cancer Res 2000, 6:50-56.
14. Angele S, Treilleux I, Taniere P, Martel-Planche G, Vuillaume M, Bailly
C, Bremond A, Montesano R, Hall J: Abnormal expression of the
ATM and TP53 genes in sporadic breast carcinomas.  Clin Can-
cer Res 2000, 6:3536-3544.
15. Yamashita H, Nishio M, Toyama T, Sugiura H, Zhang Z, Kobayashi S,
Iwase H: Coexistence of HER2 over-expression and p53 pro-
tein accumulation is a strong prognostic molecular marker
in breast cancer.  Breast Cancer Res 2004, 6:R24-30.
16. Malzahn K, Mitze M, Thoenes M, Moll R: Biological and prognostic
significance of stratified epithelial cytokeratins in infiltrating
ductal breast carcinomas.  Virchows Arch 1998, 433:119-129.
17. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, Chen B:
EGFR gene amplification in breast cancer: correlation with
epidermal growth factor receptor mRNA and protein
expression and HER-2 status and absence of EGFR-activat-
ing mutations.  Mod Pathol 2005, 18:1027-1033.
18. Endo K, Konishi A, Sasaki H, Takada M, Tanaka H, Okumura M, Kawa-
hara M, Sugiura H, Kuwabara Y, Fukai I, et al.: Epidermal growth
factor receptor gene mutation in non-small cell lung cancer
using highly sensitive and fast TaqMan PCR assay.  Lung Cancer
2005, 50:375-384.
19. Zhao X, Li C, Paez JG, Chin K, Janne PA, Chen TH, Girard L, Minna
J, Christiani D, Leo C, et al.: An integrated view of copy number
and allelic alterations in the cancer genome using single
nucleotide polymorphism arrays.  Cancer Res 2004,
64:3060-3071.
20. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A,
Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A: Gene copy
number for epidermal growth factor receptor (EGFR) and
clinical response to antiEGFR treatment in colorectal can-
cer: a cohort study.  Lancet Oncol 2005, 6:279-286.
21. Takano T, Ohe Y, Sakamoto H, Tsuta K, Matsuno Y, Tateishi U,
Yamamoto S, Nokihara H, Yamamoto N, Sekine I, et al.: Epidermal
growth factor receptor gene mutations and increased copy
numbers predict gefitinib sensitivity in patients with recur-
rent non-small-cell lung cancer.  J Clin Oncol 2005, 23:6829-6837.
22. Toyama T, Iwase H, Watson P, Muzik H, Saettler E, Magliocco A,
DiFrancesco L, Forsyth P, Garkavtsev I, Kobayashi S, Riabowol K:
Suppression of ING1 expression in sporadic breast cancer.
Oncogene 1999, 18:5187-5193.
23. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P,
Kaye FJ, Lindeman N, Boggon TJ, et al.: EGFR mutations in lung
cancer: correlation with clinical response to gefitinib ther-
apy.  Science 2004, 304:1497-1500.
24. Sasaki H, Endo K, Konishi A, Takada M, Kawahara M, Iuchi K, Mat-
sumura A, Okumura M, Tanaka H, Kawaguchi T, et al.: EGFR Muta-
tion status in Japanese lung cancer patients: genotyping
analysis using LightCycler.  Clin Cancer Res 2005, 11:2924-2929.
25. Early Breast Cancer Trialists' Collaborative Group (EBCTCG):
Effects of chemotherapy and hormonal therapy for early
breast cancer on recurrence and 15-year survival: an over-
view of the randomised trials.  Lancet 2005, 365:1687-1717.
26. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett
M, Goldhirsch A, Untch M, Mariani G, Baselga J, et al.: 2-year follow-
up of trastuzumab after adjuvant chemotherapy in HER2-
positive breast cancer: a randomised controlled trial.  Lancet
2007, 369:29-36.
27. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE,
Tan-Chiu E, Martino S, Paik S, Kaufman PA, et al.: Trastuzumab plus
adjuvant chemotherapy for operable HER2-positive breast
cancer.  N Engl J Med 2005, 353:1673-1684.
28. Mitsudomi T, Kosaka T, Endoh H, Horio Y, Hida T, Mori S, Hatooka
S, Shinoda M, Takahashi T, Yatabe Y: Mutations of the epidermal
growth factor receptor gene predict prolonged survival after
gefitinib treatment in patients with non-small-cell lung can-
cer with postoperative recurrence.  J Clin Oncol 2005,
23:2513-2520.
29. Hirsch FR, Varella-Garcia M, Cappuzzo F, McCoy J, Bemis L, Xavier
AC, Dziadziuszko R, Gumerlock P, Chansky K, West H, et al.: Com-
bination of EGFR gene copy number and protein expression
predicts outcome for advanced non-small-cell lung cancer
patients treated with gefitinib.  Ann Oncol 2007, 18:752-760.
30. Sasaki H, Endo K, Okuda K, Kawano O, Kitahara N, Tanaka H, Mat-
sumura A, Iuchi K, Takada M, Kawahara M, et al.: Epidermal growthPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Cancer 2008, 8:309 http://www.biomedcentral.com/1471-2407/8/309
Page 12 of 12
(page number not for citation purposes)
factor receptor gene amplification and gefitinib sensitivity in
patients with recurrent lung cancer.  J Cancer Res Clin Oncol
2008, 134:569-577.
31. Ma Y, Lespagnard L, Durbecq V, Paesmans M, Desmedt C, Gomez-
Galdon M, Veys I, Cardoso F, Sotiriou C, Di Leo A, et al.: Polysomy
17 in HER-2/neu status elaboration in breast cancer: effect
on daily practice.  Clin Cancer Res 2005, 11:4393-4399.
32. Pinter F, Papay J, Almasi A, Sapi Z, Szabo E, Kanya M, Tamasi A, Jori
B, Varkondi E, Moldvay J, et al.: Epidermal growth factor recep-
tor (EGFR) high gene copy number and activating mutations
in lung adenocarcinomas are not consistently accompanied
by positivity for EGFR protein by standard immunohisto-
chemistry.  J Mol Diagn 2008, 10:160-168.
33. Rakha EA, Reis-Filho JS, Ellis IO: Basal-like breast cancer: a criti-
cal review.  J Clin Oncol 2008, 26:2568-2581.
34. Turner N, Tutt A, Ashworth A: Hallmarks of 'BRCAness' in spo-
radic cancers.  Nat Rev Cancer 2004, 4:814-819.
35. Liu S, Ginestier C, Charafe-Jauffret E, Foco H, Kleer CG, Merajver SD,
Dontu G, Wicha MS: BRCA1 regulates human mammary
stem/progenitor cell fate.  Proc Natl Acad Sci USA 2008,
105:1680-1685.
36. Narod SA, Foulkes WD: BRCA1 and BRCA2: 1994 and beyond.
Nat Rev Cancer 2004, 4:665-676.
37. Schreiber V, Dantzer F, Ame JC, de Murcia G: Poly(ADP-ribose):
novel functions for an old molecule.  Nat Rev Mol Cell Biol 2006,
7:517-528.
38. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB,
Santarosa M, Dillon KJ, Hickson I, Knights C, et al.: Targeting the
DNA repair defect in BRCA mutant cells as a therapeutic
strategy.  Nature 2005, 434:917-921.
39. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Har-
ris L, Hait W, Toppmeyer D: Locoregional relapse and distant
metastasis in conservatively managed triple negative early-
stage breast cancer.  J Clin Oncol 2006, 24:5652-5657.
40. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA,
Lickley LA, Rawlinson E, Sun P, Narod SA: Triple-negative breast
cancer: clinical features and patterns of recurrence.  Clin Can-
cer Res 2007, 13:4429-4434.
41. Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Sym-
mans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al.:
Response to neoadjuvant therapy and long-term survival in
patients with triple-negative breast cancer.  J Clin Oncol 2008,
26:1275-1281.
42. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC,
Akslen LA, Nielsen TO, Foulkes WD: Use of immunohistochem-
ical markers can refine prognosis in triple negative breast
cancer.  BMC Cancer 2007, 7:134.
43. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila
DW, Sartor CI, Graham ML, Perou CM: The triple negative par-
adox: primary tumor chemosensitivity of breast cancer sub-
types.  Clin Cancer Res 2007, 13:2329-2334.
44. Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M,
Anderson K, Hess KR, Stec J, Ayers M, Wagner P, et al.: Breast can-
cer molecular subtypes respond differently to preoperative
chemotherapy.  Clin Cancer Res 2005, 11:5678-5685.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/8/309/pre
pub